By Nikhil Sharma (Reuters) -European shares reached a record high on Friday, led by technology and healthcare stocks, as ...
Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's ...
J.P. Morgan analyst Richard Vosser has maintained their neutral stance on NOVN stock, giving a Hold rating today.Invest with Confidence: ...
The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...
After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...
Reports Q4 revenue $13.2B vs. $11.4B last year. Vas Narasimhan, CEO of Novartis (NVS), said: “In our first full year as a pure-play innovative ...
Hailee Steinfeld is teaming up with Novartis to raise awareness about breast cancer with an empowering Super Bowl 59 ...
Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing in Sjögren’s ...
Novartis’ (NOVN: VX) results show the firm humming along nicely in 2024, with sales driven by continued strong performance ...
To direct more attention toward the importance of regular breast cancer screenings, Novartis is taking to one of television’s ...
Bernstein analyst Florent Cespedes maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback